Table 2.

In Vivo ³¹P Magnetic Resonance Spectroscopy of HT29 Tumors.

(A) Pre- and Post-Vehicle Treatment (N = 7)
Metabolite Ratios	Pre-Vehicle	Post-Vehicle	P†
PME/TotP	0.18 ± 0.01	0.18 ± 0.02	NS
β-NTP/TotP	0.21 ± 0.01	0.21 ± 0.01	NS
PCr/TotP	0.10 ± 0.01	0.09 ± 0.02	NS
β-NTP/Pi	3.15 ± 0.55	2.50 ± 0.35	NS
Pi/TotP	0.06 ± 0.03	0.09 ± 0.01	NS
pHi	7.12 ± 0.06	7.14 ± 0.06	NS

(B) Pre- and Post-LAQ824 Treatment (N = 11)
Metabolite ratios	Pre-LAQ824	Post-LAQ824	P
PME/TotP	0.18 ± 0.01	0.23 ± 0.01	.003
β-NTP/TotP	0.21 ± 0.01	0.13 ± 0.02	.001
PCr/TotP	0.08 ± 0.01	0.04 ± 0.01	.004
β-NTP/Pi	2.62 ± 0.33	1.09 ± 0.43	.003
Pi/TotP	0.09 ± 0.01	0.21 ± 0.03	.0002
pHi	7.08 ± 0.03	6.93 ± 0.04	.02

Data are expressed as mean ± SEM.

PME indicates phosphomonoester; TotP, total phosphorus signal; β-NTP, β-nucleoside triphosphate; Pi, inorganic phosphate; pHi, intracellular pH; PCr, phosphocreatine; NS, not statistically significant (P > .1).

^†Two-tailed paired t test was used to compare changes pre- and post-LAQ824 treatment within the same group of animals.